Outlook Therapeutics (OTLK) Operating Margin (2015 - 2025)

Outlook Therapeutics (OTLK) reported Operating Margin of 18863.9% for Q3 2025, up 1903.09% quarter-over-quarter from 1046.2% in Q2 2025.

Outlook Therapeutics (OTLK) Operating Margin (2015 - 2025) Analysis & Trends

Outlook Therapeutics (OTLK) has 6 years of Operating Margin data on file, last reported at 18863.9% in Q3 2025.

  • Operating Margin for Q3 2025 came in at 18863.9%, changed N/A year-over-year; the trailing twelve-month figure through Sep 2025 was 854.19% (changed N/A YoY), and the FY2025 annual result was 4744.25%, changed N/A from the prior year.
  • Operating Margin climbed to 18863.9% in Q3 2025 per OTLK's latest filing, from 1046.2% in the prior quarter.
  • Over five years, Operating Margin peaked at 18863.9% in Q3 2025 and troughed at 1046.2% in Q2 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Operating Margin (Qtr)
1 Alterity Therapeutics 719,706.53 Bn 719,706.50 Bn - -
2 Belite Bio 55,800.00 Bn 55,800.00 Bn - -
3 Quantum Biopharma 18,182.30 Bn 18,182.29 Bn - -
4 Legend Biotech 3,154.00 Bn 3,153.71 Bn 242.10 Mn -6.43%
5 Akari Therapeutics 1,844.30 Bn 1,844.29 Bn - -
6 Evaxion A 1,567.96 Bn 1,567.94 Bn - -
7 Psyence Biomedical 251.43 Bn 251.42 Bn - -
8 Vertex Pharmaceuticals 112.56 Bn 105.31 Bn 2.59 Bn 38.10%
9 Abivax 94.37 Bn 94.37 Bn - -
10 Outlook Therapeutics 51.56 Mn 43.81 Mn -21,888.00 -

Historic Data

Download Data
DateValue
Sep 30, 2025 18,863.90%
Jun 30, 2025 -1,046.20%
Sep 30, 2019 -216.83%
Jun 30, 2019 -966.72%
Mar 31, 2019 -1,201.86%
Dec 31, 2018 -960.78%
Sep 30, 2018 -1,608.21%
Jun 30, 2018 -935.35%
Mar 31, 2018 -884.97%
Dec 31, 2017 -411.95%
Sep 30, 2017 -100.29%
Jun 30, 2017 -2,420.14%
Mar 31, 2017 -2,585.60%
Dec 31, 2016 -5,870.30%
Sep 30, 2016 -2,011.04%
Jun 30, 2016 -4,450.95%
Mar 31, 2016 -296.91%
Dec 31, 2015 -1,649.75%
Sep 30, 2015 -3,510.23%
Jun 30, 2015 -853.02%